An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis

Abstract

Context: Denosumab is widely used for bone diseases with increased bone resorption. Its effectiveness in patients with severe secondary hyperparathyroidism on dialysis is unclear. Objective: This study aimed to evaluate the efficacy and safety of denosumab in patients with severe secondary hyperparathyroidism who are on dialysis. Design: This 6-month prospective, open-labeled study evaluated 12 patients (five women, seven men; mean age 53.5±3.8 y). All had intact PTH (iPTH; > 1000 pg/mL), low bone mass (T-score